ã»ã¯ã¿:
å¥åº·ç®¡ç
æ¥ç:
ãã€ãªãã¯ãããžãŒ
ã¢ã¯ã»ã¹ãååŸ
ãã£ã³ã¬ã³ãžæ ªã®æ Œä»ã
ãã£ã³ã¬ã³ãžæ ªã®æ Œä»ã
ãã®æéãã©ã³ã§ã¯ãå¶éãªããµãŒãã¹ãå©çšã§ãããã¹ãŠã®æ
å ±ãå©çšå¯èœã«ãªããŸãã
ãã£ã³ã¬ã³ãžã®è©äŸ¡
ä»åŸã®ã€ãã³ã Chemomab Therapeutics Ltd DRC
ãã¹ãŠã®ã€ãã³ã
ä»åŸã®ã€ãã³ãã¯äºå®ãããŠããŸãã
èŠçŽåæ Chemomab Therapeutics Ltd DRC
ã¢ã¯ã»ã¹ãååŸ
ãã£ã³ã¬ã³ãžæ ªã®æ Œä»ã
ãã£ã³ã¬ã³ãžæ ªã®æ Œä»ã
ãã®æéãã©ã³ã§ã¯ãå¶éãªããµãŒãã¹ãå©çšã§ãããã¹ãŠã®æ
å ±ãå©çšå¯èœã«ãªããŸãã
売äžé«ãšçŽå©ç Chemomab Therapeutics Ltd DRC
ãã¹ãŠã®ãã©ã¡ãŒã¿
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
äœæ:
Building 7, Tel Aviv, Israel, 6158002
äŒç€Ÿå:
Chemomab Therapeutics Ltd DRC
çºè¡è
ãã£ãã«ãŒ:
CMMB
ISIN:
US16385C1045
åœ:
ã¢ã¡ãªã«åè¡åœ
亀æ:
NASDAQ
é貚:
$
äžå Žæ¥:
2019-02-12
ã»ã¯ã¿:
å¥åº·ç®¡ç
æ¥ç:
ãã€ãªãã¯ãããžãŒ
ãµã€ã:
https://www.chemomab.com
https://www.chemomab.com
